KLK6
KLK6 (kallikrein related peptidase 6, also known as neurosin, Bssp, PRSS9 and PRSS18) is a secreted serine protease of the kallikrein subfamily. It cleaves substrates including amyloid precursor protein, myelin basic protein and extracellular matrix proteins. Browse Assay Genie's current range of KLK6 research reagents below, or read on for the biology behind the target.
KLK6 is a serine protease that shows a preference for arginine over lysine at the substrate P1 position, and for serine or proline at P2. It is active against amyloid precursor protein, myelin basic protein, gelatin and casein, as well as extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen. It also degrades alpha-synuclein and prevents its polymerisation, which suggests a possible role in Parkinson disease and other synucleinopathies. It may also be involved in regulating axon outgrowth after spinal cord injury.
The KLK6 gene encodes a member of the kallikrein subfamily of the peptidase S1 family, and sits in a kallikrein gene cluster on chromosome 19. The encoded preproprotein is proteolytically processed to give the mature protease. Alternative splicing produces multiple transcript variants, at least one of which encodes an isoform that is itself proteolytically processed. UniProt records the protein mainly as secreted, with additional annotations for the nucleolus, cytoplasm, mitochondrion and microsome. Expression is regulated by steroid hormones.
Researchers study KLK6 in several disease settings. Many kallikreins are implicated in carcinogenesis and are being explored as cancer biomarkers, and KLK6 may be elevated in multiple human cancers and in serum from psoriasis patients. Tumour cells treated with a neutralising KLK6 antibody migrate less than control cells, pointing to a role in invasion and metastasis. Its cleavage of amyloid precursor protein and alpha-synuclein links it to Alzheimer's and Parkinson's disease respectively. Earlier names include protease, serine, 18 and kallikrein 6 (neurosin, zyme).
KLK6 degrades alpha-synuclein and may cleave amyloid precursor protein, linking it to Parkinson's and Alzheimer's disease.
Kallikreins are explored as cancer biomarkers, and KLK6 may be elevated in multiple human cancers.
Neutralising KLK6 antibody reduces tumour cell migration, and the protease acts on extracellular matrix proteins such as laminin and collagen.
KLK6 may be involved in regulating axon outgrowth following spinal cord injury, and it acts on myelin basic protein.
KLK6 is a secreted serine protease that prefers Arg at P1 and Ser or Pro at P2. It cleaves amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins, and degrades alpha-synuclein, preventing its polymerisation.
KLK6 is also called neurosin, Bssp, PRSS9, PRSS18 and Klk7. Earlier names include protease, serine, 18 and kallikrein 6 (neurosin, zyme). The HGNC name is kallikrein related peptidase 6, and UniProt lists the protein as Kallikrein-6.
KLK6 may be elevated in multiple human cancers and in serum from psoriasis patients, and is implicated in Alzheimer's and Parkinson's disease. The rat ortholog is Klk6 and the mouse ortholog is listed as Klk1; check the datasheet of any product for its validated reactivity.
Other members of the kallikrein family of serine proteases, several of which are studied as disease biomarkers.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q92876; product specifications from Assay Genie datasheets.